Compare RGS & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGS | IPSC |
|---|---|---|
| Founded | 1922 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.3M | 58.3M |
| IPO Year | 1991 | 2021 |
| Metric | RGS | IPSC |
|---|---|---|
| Price | $25.84 | $1.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 5.7K | ★ 1.7M |
| Earning Date | 02-11-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.05 | N/A |
| EPS | ★ 45.08 | N/A |
| Revenue | ★ $223,032,000.00 | $113,337,000.00 |
| Revenue This Year | N/A | $1,590.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.58 | ★ N/A |
| Revenue Growth | 13.98 | ★ 4122.69 |
| 52 Week Low | $15.00 | $0.34 |
| 52 Week High | $31.50 | $1.34 |
| Indicator | RGS | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 35.83 | 85.53 |
| Support Level | $24.98 | $0.90 |
| Resistance Level | $27.75 | $1.05 |
| Average True Range (ATR) | 0.77 | 0.17 |
| MACD | -0.31 | 0.06 |
| Stochastic Oscillator | 11.66 | 90.72 |
Regis Corporation owns, franchises, and operates beauty salons in North America and the U.K., serving mainly price-conscious customers. Its salons, located mostly in strip malls, shopping centers, and Walmart stores, offer services like haircutting, styling, shampooing, conditioning, and hair coloring, along with hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, and Cost Cutters. Regis generates the majority of its revenue from these mass-market locations and reports operations in two segments: franchise and company-owned, with services making up about 94% of company-owned salon sales.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.